• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.

作者信息

Scholtes Rosalie A, Hesp Anne C, Mosterd Charlotte M, Geurts Frank, Hoorn Ewout J, Touw Daan J, Krebber Merle M, Joles Jaap A, Heerspink Hiddo J L, van Raalte Daniël H

机构信息

Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VUMC, the Netherlands (R.A.S., A.C.H., C.M.M., D.H.v.R.).

Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands (F.G., E.J.H.).

出版信息

Circulation. 2022 Dec 13;146(24):1895-1897. doi: 10.1161/CIRCULATIONAHA.122.061033. Epub 2022 Dec 12.

DOI:10.1161/CIRCULATIONAHA.122.061033
PMID:36508495
Abstract
摘要

相似文献

1
Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.血管紧张素受体阻断、单独的钠-葡萄糖协同转运蛋白-2抑制及其联合应用对肾脏血流动力学的影响：一项2型糖尿病患者的交叉随机试验
Circulation. 2022 Dec 13;146(24):1895-1897. doi: 10.1161/CIRCULATIONAHA.122.061033. Epub 2022 Dec 12.
2
Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.血管紧张素系统阻滞剂和钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病患者促红细胞生成素分泌的竞争作用。
Am J Nephrol. 2020;51(5):349-356. doi: 10.1159/000507272. Epub 2020 Apr 2.
3
A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂开创糖尿病肾病治疗新纪元。
J Diabetes Investig. 2022 May;13(5):765-767. doi: 10.1111/jdi.13747. Epub 2022 Feb 3.
4
Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.钠-葡萄糖共转运蛋白 2 抑制剂——治疗慢性肾脏病的神奇药物，无论糖尿病状况如何：来自专门针对肾脏疾病的 CREDENCE 和 DAPA-CKD 试验的经验。
Int J Mol Sci. 2022 Nov 9;23(22):13749. doi: 10.3390/ijms232213749.
5
Therapeutic transformation for diabetic kidney disease.糖尿病肾病的治疗转变。
Kidney Int. 2021 Feb;99(2):301-303. doi: 10.1016/j.kint.2020.10.003.
6
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.在糖尿病肾病患者中，依折麦布联合钠-葡萄糖共转运蛋白 2 抑制剂治疗可降低血清钾升高的幅度：两项 III 期研究的亚分析。
J Diabetes Investig. 2022 Jul;13(7):1190-1202. doi: 10.1111/jdi.13778. Epub 2022 Apr 21.
7
Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂作为慢性肾脏病的一线通用治疗药物。
Nefrologia (Engl Ed). 2022 Jul-Aug;42(4):390-403. doi: 10.1016/j.nefroe.2022.08.001.
8
Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.钠-葡萄糖协同转运蛋白2抑制剂对心肾轴的保护作用：肾脏生理学相关最新机制见解的更新
Eur J Intern Med. 2022 Jun;100:13-20. doi: 10.1016/j.ejim.2022.03.031. Epub 2022 Apr 9.
9
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂：糖尿病肾病的一种潜在新疗法？
Nephron. 2017;137(1):64-67. doi: 10.1159/000450895. Epub 2017 Jul 26.
10
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.在糖尿病前期阶段进行短暂的血管紧张素II阻断可减轻2型糖尿病大鼠肾损伤的发展。
J Am Soc Nephrol. 2005 Mar;16(3):703-11. doi: 10.1681/ASN.2004080649. Epub 2005 Jan 12.

引用本文的文献

1
Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study.肾素-血管紧张素系统（RAS）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂单用或联用对糖尿病合并高血压患者终末期肾病和/或全因死亡的影响：一项全国性队列研究
Cardiovasc Diabetol. 2025 Jul 14;24(1):288. doi: 10.1186/s12933-025-02846-x.
2
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.恩格列净与利格列汀单药及联合治疗和格列齐特相比，对超重2型糖尿病患者空腹及餐后肾脏血流动力学的影响（RACELINES）：一项随机、双盲试验
Diabetes Obes Metab. 2025 Jul;27(7):3943-3956. doi: 10.1111/dom.16431. Epub 2025 May 6.
3
The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals.恩格列净、氯沙坦及其联合用药对全身和肾脏血流动力学的反应存在个体差异。
J Nephrol. 2025 Apr 12. doi: 10.1007/s40620-025-02289-3.
4
Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病患者肾脏血流动力学的影响：生理学及临床意义
Clin Kidney J. 2024 Nov 27;18(1):sfae370. doi: 10.1093/ckj/sfae370. eCollection 2025 Jan.
5
New insights in the treatment of DKD: recent advances and future prospects.糖尿病肾病治疗的新见解：近期进展与未来展望。
BMC Nephrol. 2025 Feb 11;26(1):72. doi: 10.1186/s12882-025-03953-3.
6
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.联合治疗：改善慢性肾脏病肾脏和心血管结局的一种新兴模式。
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i3-i17. doi: 10.1093/ndt/gfae212.
7
Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin.恩格列净对肾脏和全身血流动力学影响的随机、安慰剂对照试验
Kidney Int Rep. 2024 Oct 29;10(1):134-144. doi: 10.1016/j.ekir.2024.10.019. eCollection 2025 Jan.
8
Combination therapy for kidney disease in people with diabetes mellitus.糖尿病患者肾病的联合治疗。
Nat Rev Nephrol. 2024 Jul;20(7):433-446. doi: 10.1038/s41581-024-00827-z. Epub 2024 Apr 3.
9
Exposure-Response Analysis of the Sodium-Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂达格列净和恩格列净对2型糖尿病患者肾脏血流动力学的暴露-反应分析
J Pers Med. 2023 Apr 27;13(5):747. doi: 10.3390/jpm13050747.